{
    "clinical_study": {
        "@rank": "67189", 
        "arm_group": [
            {
                "arm_group_label": "Liposome Bupivacaine", 
                "arm_group_type": "Experimental", 
                "description": "Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline"
            }, 
            {
                "arm_group_label": "Bupivacaine", 
                "arm_group_type": "Active Comparator", 
                "description": "Single shot femoral nerve block with 20cc of 0.25% bupivacaine"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the quality and duration of pain relief after a\n      total knee replacement provided by a single shot of standard bupivacaine versus a single\n      shot of liposomal bupivacaine, at the site of the femoral nerve. It is hypothesized that the\n      liposomal bupivacaine formulation will provide more effective pain relief than standard\n      bupivacaine."
        }, 
        "brief_title": "Efficacy of Single Injection Femoral Nerve Block With Liposomal Bupivacaine for Total Knee Arthroplasty", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Total Knee Arthroplasty", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, \u226518 years of age\n\n          2. Scheduled to undergo primary unilateral TKA under general anesthesia.\n\n          3. American Society of Anesthesiology (ASA) Physical Status I-III\n\n          4. Able to demonstrate motor function by performing a 20-meter walk, and sensory\n             function by exhibiting sensitivity to cold.\n\n          5. Able to provide informed consent, adhere to the study visit schedule, and complete\n             all study assessments.\n\n        Exclusion Criteria:\n\n          1. Currently pregnant, nursing, or planning to become pregnant during the study or\n             within 1 month after study drug administration.\n\n          2. Planned concurrent surgical procedure (e.g., bilateral TKA).\n\n          3. Body weight < 50 kg (110 pounds) or a body mass index \u2265 40 kg/m2.\n\n          4. Contraindication to any of the pain-control agents planned for postsurgical use\n             (i.e., morphine, hydromorphone, oxycodone, bupivacaine).\n\n          5. Previous participation in a liposome bupivacaine study.\n\n          6. History of, suspected, or known addiction to or abuse of illicit drug(s),\n             prescription medicine(s), or alcohol within the past 2 years.\n\n          7. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the\n             opinion of the investigator, could interfere with study assessments or compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977339", 
            "org_study_id": "13-0060"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liposome Bupivacaine", 
                "description": "10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline", 
                "intervention_name": "Liposome Bupivacaine", 
                "intervention_type": "Drug", 
                "other_name": "Exparel"
            }, 
            {
                "arm_group_label": "Bupivacaine", 
                "description": "20 cc of 0.25% bupivacaine", 
                "intervention_name": "Bupivacaine", 
                "intervention_type": "Drug", 
                "other_name": "Bupivacaine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bupivacaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Femoral Nerve Block", 
            "Liposomal Bupivacaine"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10025"
                }, 
                "name": "St. Luke's-Roosevelt Hospital Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blinded, Control Trial to Evaluate the Efficacy of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Unilateral Total Knee Arthroplasty", 
        "other_outcome": [
            {
                "description": "Sensation in the distribution of the femoral nerve as assessed by temperature using an alcohol swab (0=no sensation, 1=decreased sensation, 2=normal).", 
                "measure": "Sensory mapping (temperature)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "description": "The ability to walk 20 meters unassisted with the optional use of a 4-legged walker at baseline, and at 24, 48 and 72 hours post-operatively.", 
                "measure": "Motor function assessment", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }
        ], 
        "overall_contact": {
            "email": "alishariatmd@gmail.com", 
            "last_name": "Ali Shariat, MD", 
            "phone": "914-409-5023"
        }, 
        "overall_official": {
            "affiliation": "St. Luke's-Roosevelt Hospital Center", 
            "last_name": "Ali Shariat, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare the cumulative 72 hour opiate consumption after total knee arthroplasty (TKA)in patients who received a single dose of liposome bupivacaine with those who received a single shot femoral nerve block with 0.25% bupivacaine.", 
            "measure": "Opiate consumption", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patients will be asked to describe the pain intensity under two circumstances: pain at rest, and pain on movement. Postoperative pain intensity will be evaluated using the Visual Analogue Scale (VAS) system at 1, 4, 8, 12, 24, 48 and 72 hours. The VAS used will be the 11 point verbal response pain scale with 0 being no pain at all and 10 being the worst possible pain. The patients will be asked to rate their pain levels using this numeric scale.", 
            "measure": "Post-operative VAS scores", 
            "safety_issue": "No", 
            "time_frame": "1 hr, 4 hrs, 8 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs"
        }, 
        "source": "St. Luke's-Roosevelt Hospital Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Luke's-Roosevelt Hospital Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}